Skip to main content
SpringerLink
Log in
Book cover

Endocrinology of the Testis and Male Reproduction pp 1199–1209Cite as

Therapy with Antiandrogens in Gender Dysphoric Natal Males

  • Reference work entry
  • First Online:

Part of the book series: Endocrinology ((ENDOCR))

Abstract

In adult gender dysphoric natal males, where full development of male secondary sexual characteristics has already taken place, the goal of cross-sex hormonal therapy is the suppression of testosterone secretion to achieve regression of male characteristics and the development of feminine secondary sexual characteristics. For this reason, in transwomen an almost complete suppression of endogenous androgen production and action with combined administration of estrogens is required. The aim of therapy is to maintain hormone levels within the normal physiological range for the individual’s desired gender. Practice guidelines describe eligibility for puberty suppression in adolescents that have met the criteria for gender dysphoria and that have experienced at least Tanner stage 2 puberty. In these subjects if dysphoria persists, cross-hormonal therapy is generally started after 16 years of age.

This is a preview of subscription content, log in via an institution.

References

  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013. Available from: dsm.psychiatryonline.org. Accessed 1 June 2016.

    Book  Google Scholar 

  • Blankenstein MA, Verheijen FM, Jacobs JM, et al. Occurrence, regulation, an significance of progesterone receptors in human meningioma. Steroids. 2000;65:795–800.

    Article  CAS  PubMed  Google Scholar 

  • Bunck MC, Debono M, Giltay EJ, et al. Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. BMJ Case Rep. 2009;2009:bcr02.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cea-Soriano L, Blenk T, Wallander M-A, et al. Hormonal therapies and meningioma: is there a link? Cancer Epidemiol. 2012;36:198–205.

    Article  CAS  PubMed  Google Scholar 

  • Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2011;13:165–232.

    Article  Google Scholar 

  • Cunha FS, Domenice S, Câmara VL, et al. Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy. Andrologia. 2015;47(6):680–4.

    Article  CAS  PubMed  Google Scholar 

  • Dahl M, Feldman JL, Goldberg J, et al. Endocrine therapy for transgender adults in British Columbia: suggested guidelines. Vancouver: Transgender Health Program; 2006. Available from: http://transhealth.vch.ca/. Accessed 1 June 2016.

    Google Scholar 

  • De Vries AL, Cohen-Kettenis PT. Clinical management of gender dysphoria in children and adolescents: the Dutch approach. J Homosex. 2012;59:301–20.

    Article  PubMed  Google Scholar 

  • Ettner R. Care of the elderly transgender patient. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):580–4.

    Article  PubMed  Google Scholar 

  • Fisher AD, Ristori J, Bandini E, et al. Medical treatment in gender dysphoric adolescents endorsed by SIAMS-SIESIEDP- ONIG. J Endocrinol Investig. 2014;37:675–87.

    Article  CAS  Google Scholar 

  • Gava G, Cerpolini S, Martelli V, et al. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. Clin Endocrinol. 2016;85(2):239–46.

    Article  CAS  Google Scholar 

  • Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med. 2007;357:2411–2.

    Article  CAS  PubMed  Google Scholar 

  • Gil M, Oliva B, Timoner J, et al. Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol. 2011;72:965–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gooren LJ. Clinical practice. Care of transsexual persons. N Engl J Med. 2011;364:1251–7.

    Article  CAS  PubMed  Google Scholar 

  • Gulmez SE, Lassen AT, Aalykke C, et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol. 2008;66:294–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2009;94:3132–54.

    Article  CAS  PubMed  Google Scholar 

  • Knezevich EL, Viereck LK, Drincic AT. Medical management of adult transsexual persons. Pharmacotherapy. 2012;32:54–66.

    Article  CAS  PubMed  Google Scholar 

  • Meriggiola MC, Bremner WJ, Costantino A, et al. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril. 1997;68(5):844–50.

    Article  CAS  PubMed  Google Scholar 

  • Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab. 2003;88:3467–73.

    Article  CAS  PubMed  Google Scholar 

  • Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2008;159:197–202.

    Article  CAS  PubMed  Google Scholar 

  • Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxford). 2010;72:214–31.

    Article  Google Scholar 

  • Ott J, Kaufmann U, Bentz EK, et al. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril. 2010;93:1267–72.

    Article  PubMed  Google Scholar 

  • Royal College of Psychiatrists. Good practice guidelines or the assessment and treatment of adults with gender dysphoria. Royal College of Psychiatrists, 2013. Available from: http://www.rcpsych.ac.uk/usefulresources/publications/collegereports/cr/cr181.aspx. Accessed 18 June 2016.

  • Savidou I, Deutsch M, Soultati AS, et al. Hepatotoxicity induced by cyproterone acetate: a report of three cases. World J Gastroenterol. 2006;12:7551–5.

    Article  PubMed  PubMed Central  Google Scholar 

  • Schagen SE, Cohen-Kettenis PT, Delemarre-van de Waal HA, et al. Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med. 2016;13(7):1125–32.

    Article  PubMed  Google Scholar 

  • Seal LJ, Franklin S, Richards C, et al. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. J Clin Endocrinol Metab. 2012;97:4422–8.

    Article  CAS  PubMed  Google Scholar 

  • Spack NP. Management of transgenderism. JAMA. 2013;309:478–84.

    Article  CAS  PubMed  Google Scholar 

  • Tangpricha V, Ducharme SH, Barber TW, et al. Endocrinologic treatment of gender identity disorders. Endocr Pract. 2003;9:12–21.

    Article  PubMed  Google Scholar 

  • Ter Wengel PV, Martin E, Gooren L, et al. Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature. Andrologia. 2016. doi:10.1111/and.12550. [Epub ahead of print].

    PubMed  Google Scholar 

  • Toorians AW, Thomasse MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab. 2003;88(12):5723–9.

    Article  CAS  PubMed  Google Scholar 

  • Wigertz A, Lonn S, Hall P, et al. Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomark Prev. 2008;17:2663–70.

    Article  Google Scholar 

  • Wilson AC, Meethal SV, Bowen RL, et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007;16:1851–63.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynecology and Physiopathology of Human Reproduction, S. Orsola-Malpighi Hospital, Department of Medical and Surgical Science, University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy

    Giulia Gava, Renato Seracchioli & Maria Cristina Meriggiola

Authors
  1. Giulia Gava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renato Seracchioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Cristina Meriggiola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Cristina Meriggiola .

Editor information

Editors and Affiliations

  1. Unit of Endocrinology Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

    Manuela Simoni

  2. Faculty of Medicine Department of Surgery and Cancer, Imperial College London, London, United Kingdom

    Ilpo T. Huhtaniemi

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Gava, G., Seracchioli, R., Meriggiola, M.C. (2017). Therapy with Antiandrogens in Gender Dysphoric Natal Males. In: Simoni, M., Huhtaniemi, I. (eds) Endocrinology of the Testis and Male Reproduction. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-44441-3_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44441-3_42

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44440-6

  • Online ISBN: 978-3-319-44441-3

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation